phkineticaФармакокинетика и ФармакодинамикаPharmacokinetics and Pharmacodynamics2587-78362686-8830ООО «Издательство ОКИ»10.37489/2587-7836-2024-1-4-13GCGFPSphkinetica-405Research ArticleАКТУАЛЬНЫЙ ОБЗОРCURRENT REVIEWSСистематический анализ фармакологии миоинозитола и D-хироинозитолаSystematic analysis of the pharmacology of myoinositol and D-chiroinositolahttps://orcid.org/0000-0002-5042-4886БогачеваТ. Е.BogachevaT. E.

Богачева Татьяна Евгеньевна – к. м. н., доцент кафедры фармакологии

Иваново

Tatiana E. Bogacheva – PhD, Cand. Sci. Med., Associate Professor of the Department of Pharmacology

Ivanovo

https://orcid.org/0000-0002-7663-710XГромоваО. А.GromovaO. A.

Громова Ольга Алексеевна – д. м. н, профессор, в. н. с. 

Москва

Olga A. Gromova – Dr. Sci. (Med.), Professor, Leading researcher

Moscow

unesco.gromova@gmail.comhttps://orcid.org/0000-0002-2659-7998ТоршинИ. Ю.TorshinI. Yu.

Торшин Иван Юрьевич – к. ф–м. н., к. х. н., в. н. с.

Москва

Ivan Yu. Torshin – PhD, Cand. Physico-Mathematical Sci., Cand. Chemical Sci., Leading researcher

Moscow

ФГБОУ ВО «Ивановский государственный медицинский университет» Минздрава РоссииРоссияFSBEI HE «Ivanovo State Medical University» of MOH of RussiaRussian FederationФГУ «Федеральный исследовательский центр «Информатика и управление» РАН» (ФИЦ ИУ РАН)РоссияFRC «Computer Science and Control»Russian Federation20242506202401413Copyright © Богачева Т.Е., Громова О.А., Торшин И.Ю., 20242024Богачева Т.Е., Громова О.А., Торшин И.Ю.Bogacheva T.E., Gromova O.A., Torshin I.Y.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pharmacokinetica.ru/jour/article/view/405

В статье представлен анализ публикаций по миоинозитолу с целью уточнения возможностей назначения препаратов на его основе. Миоинозитол – один из эндогенных метаболитов человека, оказывающий существенное воздействие на функционирование клеток и тканей всего тела. Основной функцией миоинозитола и его производных является участие во внутриклеточной передаче сигнала и обеспечение функционирования таких важнейших рецепторов, как рецепторы инсулина, катехоламинов, метаботропные рецепторы различных нейромедиаторов, факторов роста и др. Миоинозитол – основа для синтеза важной группы сигнальных молекул, инозитолфосфатов, которые опосредуют передачу сигнала от рецепторов ростовых факторов и нейротрансмиттеров. Большинство инозитолзависимых белков с известными функциями необходимы для жизнедеятельности сердечно-сосудистой, иммунной системы, для структуры соединительной ткани. Не менее важна роль миоинозитола в поддержании функционирования ЦНС (включая нейротрофические и нейропротекторные роли), обмене сахаров (прежде всего сигнальном каскаде инсулина) и функционировании почек и печени. Дотации миоинозитола способствуют профилактике фолатрезистентных пороков развития и нейропротекции мозга в условиях стресса.

The article presents an analysis of publications on myoinositol in order to clarify the possibilities of prescribing drugs based on it. Myoinositol is one of the endogenous human metabolites that has a significant effect on the functioning of cells and tissues of the whole body. The main function of myoinositol and its derivatives is to participate in intracellular signal transmission and ensure the functioning of such important receptors as insulin receptors, catecholamines, metabotropic receptors of various neurotransmitters, growth factors, etc. (Myoinositol is the basis for the synthesis of an important group of signaling molecules, inositol phosphates, which mediate signal transmission from growth factor receptors and neurotransmitters). Most inositol-dependent proteins with known functions are necessary for the vital functions of the cardiovascular, immune system, and connective tissue structure. Equally important is the role of myoinositol in maintaining the functioning of the central nervous system (including neurotrophic and neuroprotective roles), sugar metabolism (primarily the signaling cascade of insulin) and the functioning of the kidneys and liver. Myoinositol subsidies contribute to the prevention of folate-resistant malformations and neuroprotection of the brain under stress.

миоинозитолD-хироинозитолгепатопротекциянейроцитологиянейропротекциястеатогепатитметаболизмmyoinositolD-chiro inositolhepatoprotectionneurocytologyneuroprotectionsteatohepatitismetabolismReferencesDinicola S, Minini M, Unfer V, et al. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. Int J Mol Sci. 2017 Oct 20;18(10):2187. doi: 10.3390/ijms18102187.Dinicola S, Minini M, Unfer V, et al. Nutritional and Acquired Deficiencies in Inositol Bioavailability. Correlations with Metabolic Disorders. Int J Mol Sci. 2017 Oct 20;18(10):2187. doi: 10.3390/ijms18102187.Wong YH, Kalmbach SJ, Hartman BK, Sherman WR. Immunohistochemical staining and enzyme activity measurements show myo-inositol-1-phosphate synthase to be localized in the vasculature of brain. J Neurochem. 1987 May;48(5):1434-42. doi: 10.1111/j.1471-4159.1987.tb05682.x.Wong YH, Kalmbach SJ, Hartman BK, Sherman WR. Immunohistochemical staining and enzyme activity measurements show myo-inositol-1-phosphate synthase to be localized in the vasculature of brain. J Neurochem. 1987 May;48(5):1434-42. doi: 10.1111/j.1471-4159.1987.tb05682.x.Loewus MW, Loewus FA, Brillinger GU, et al. Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J Biol Chem. 1980 Dec 25;255(24):11710-2.Loewus MW, Loewus FA, Brillinger GU, et al. Stereochemistry of the myo-inositol-1-phosphate synthase reaction. J Biol Chem. 1980 Dec 25;255(24):11710-2.Kwon HM, Yamauchi A, Uchida S, et al. Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem. 1992 Mar 25;267(9):6297-301.Kwon HM, Yamauchi A, Uchida S, et al. Cloning of the cDNa for a Na+/myo-inositol cotransporter, a hypertonicity stress protein. J Biol Chem. 1992 Mar 25;267(9):6297-301.Hitomi K, Tsukagoshi N. cDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family. Biochim Biophys Acta. 1994 Mar 23;1190(2):469-72. doi: 10.1016/0005-2736(94)90110-4.Hitomi K, Tsukagoshi N. cDNA sequence for rkST1, a novel member of the sodium ion-dependent glucose cotransporter family. Biochim Biophys Acta. 1994 Mar 23;1190(2):469-72. doi: 10.1016/0005-2736(94)90110-4.Garzon S, Laganà AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol. 2019 Sep;15(9):697-703. doi: 10.1080/17425255.2019.1651839.Garzon S, Laganà AS, Monastra G. Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. Expert Opin Drug Metab Toxicol. 2019 Sep;15(9):697-703. doi: 10.1080/17425255.2019.1651839.Berry GT, Mallee JJ, Kwon HM, et al. The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning andlocalization to chromosome 21. Genomics. 1995 Jan 20;25(2):507-13. doi: 10.1016/0888-7543(95)80052-n.Berry GT, Mallee JJ, Kwon HM, et al. The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning andlocalization to chromosome 21. Genomics. 1995 Jan 20;25(2):507-13. doi: 10.1016/0888-7543(95)80052-n.Miyakawa H, Woo SK, Dahl SC, et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci USA. 1999 Mar 2;96(5):2538-42. doi: 10.1073/pnas.96.5.2538.Miyakawa H, Woo SK, Dahl SC, et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc Natl Acad Sci USA. 1999 Mar 2;96(5):2538-42. doi: 10.1073/pnas.96.5.2538.Majunder A, Biswas B. (Eds.) Biology of inositols and phosphoinositides. Subcellular Biochemistry. Springer: New York, NY, USA, 2006.Majunder A, Biswas B. (Eds.) Biology of inositols and phosphoinositides. Subcellular Biochemistry. Springer: New York, NY, USA, 2006.Лиманова О.А., Громова О.А., Торшин И.Ю., и др. Систематический анализ молекулярно-физиологических эффектов мио-ино-зитола: данные молекулярной биологии, экспериментальной и клинической медицины. Эффективная фармакотерапия. 2013;28:32-41.Limanova OA, Gromova OA, Torshin IYu, et al. Systematic analysis of molecular mechanisms and physiological effects of myo-inositol: findings of molecular biology, experimental and clinical medicine. Effektivnaya farmakoterapiya. 2013;28:32-41. (In Russ.)Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47-60. doi: 10.1080/15604280212528.Larner J. D-chiro-inositol--its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3(1):47-60. doi: 10.1080/15604280212528.Rapiejko PJ, Northup JK, Evans T, et al. G-proteins of fat-cells. Role in hormonal regulation of intracellular inositol 1,4,5-trisphosphate. Biochem J. 1986 Nov 15;240(1):35-40. doi: 10.1042/bj2400035.Rapiejko PJ, Northup JK, Evans T, et al. G-proteins of fat-cells. Role in hormonal regulation of intracellular inositol 1,4,5-trisphosphate. Biochem J. 1986 Nov 15;240(1):35-40. doi: 10.1042/bj2400035.Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. 1980 Sep;33(9):1954-67. doi: 10.1093/ajcn/33.9.1954.Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr. 1980 Sep;33(9):1954-67. doi: 10.1093/ajcn/33.9.1954.Hurrell RF. Influence of vegetable protein sources on trace element and mineral bioavailability. J Nutr. 2003 Sep;133(9):2973S-7S. doi: 10.1093/jn/133.9.2973S.Hurrell RF. Influence of vegetable protein sources on trace element and mineral bioavailability. J Nutr. 2003 Sep;133(9):2973S-7S. doi: 10.1093/jn/133.9.2973S.Торшин И.Ю., Громова О.А., Тетруашвили Н.К. Хемотранскриптомный анализ синергизма D-хироинозитола и миоинозитола в контексте постгеномнойфармакологии. Акушерство и гинекология. 2022;(9):135-145.Torshin IYu, Gromova OA, Tetruashvili NK. Chemotranscriptome analysis of synergism between D-chiroinositol and myoinositol in the context of postgenomic pharmacology. Obstetrics and gynecology. 2022;(9):135-145. (In Russ.). doi: 10.18565/aig.2022.9.135-145.Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. Int J Endocrinol. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450.Bevilacqua A, Bizzarri M. Inositols in Insulin Signaling and Glucose Metabolism. Int J Endocrinol. 2018 Nov 25;2018:1968450. doi: 10.1155/2018/1968450.Hong JH, Jang HW, Kang YE, et al. Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers. 2012;33(4):193-9. doi: 10.3233/DMA-2012-0925.Hong JH, Jang HW, Kang YE, et al. Urinary chiro- and myo-inositol levels as a biological marker for type 2 diabetes mellitus. Dis Markers. 2012;33(4):193-9. doi: 10.3233/DMA-2012-0925.Hacibekiroğlu M, Akçay T. The role of plasma, erythrocyte and platelet myo-inositol levels in the development of diabetic microangiopathy. Diabetes Res. 1994;25(4):173-9.Hacibekiroğlu M, Akçay T. The role of plasma, erythrocyte and platelet myo-inositol levels in the development of diabetic microangiopathy. Diabetes Res. 1994;25(4):173-9.Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972-5. doi: 10.1111/j.1464-5491.2011.03284.x.Corrado F, D'Anna R, Di Vieste G, Giordano D, Pintaudi B, Santamaria A, Di Benedetto A. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med. 2011 Aug;28(8):972-5. doi: 10.1111/j.1464-5491.2011.03284.x.Доброхотова Ю.Э., Громова О.А., Духанин А.С. и др. Инозитолы: фармакология и данные клинических исследований. Современное состояние вопроса и перспективы. РМЖ. Мать и дитя. 2022;5(4):309-319.Dobrokhotova YuE, Gromova OA, Dukhanin AS et al. Inositols: pharmacology and findings of clinical trials. Current evidence and prospects. Russian Journal of Woman and Child Health. 2022;5(4):309-319 (In Russ.). doi: 10.32364/2618-8430-2022-5-4-309-319.Melmed S, Lewin LM, Bank H. Myo-inositol clearance in renal failure and in patients with normal kidney function. Am J Med Sci. 1977 Jul-Aug;274(1):55-9. doi: 10.1097/00000441-197707000-00007.Melmed S, Lewin LM, Bank H. Myo-inositol clearance in renal failure and in patients with normal kidney function. Am J Med Sci. 1977 Jul-Aug;274(1):55-9. doi: 10.1097/00000441-197707000-00007.Rysz J, Bartnicki P, Błaszczak R, Kujawski K, Ciałkowska-Rysz A, Olszewski R, Markuszewski L. Przeciwzapalne działanie mioinozytolu w przewlekłej niewydolności nerek [Anti-inflammatory action of myoinositol in renal insufficiency]. Pol Merkur Lekarski. 2006 Feb;20(116):180-3. Polish.Rysz J, Bartnicki P, Błaszczak R, Kujawski K, Ciałkowska-Rysz A, Olszewski R, Markuszewski L. Przeciwzapalne działanie mioinozytolu w przewlekłej niewydolności nerek [Anti-inflammatory action of myoinositol in renal insufficiency]. Pol Merkur Lekarski. 2006 Feb;20(116):180-3. Polish.Han W, Gills JJ, Memmott RM, et al. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila). 2009 Apr;2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209.Han W, Gills JJ, Memmott RM, et al. The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. Cancer Prev Res (Phila). 2009 Apr;2(4):370-6. doi: 10.1158/1940-6207.CAPR-08-0209.Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004 Jun;127(Pt 6):1361-9. doi: 10.1093/brain/awh153.Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain. 2004 Jun;127(Pt 6):1361-9. doi: 10.1093/brain/awh153.Young GB, Hader WJ, Hiscock M, et al. The role of myo-inositol in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1986 Mar;49(3):265-72. doi: 10.1136/jnnp.49.3.265.Young GB, Hader WJ, Hiscock M, et al. The role of myo-inositol in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1986 Mar;49(3):265-72. doi: 10.1136/jnnp.49.3.265.Walecki J, Barcikowska M, Ćwikła JB, Gabryelewicz T. N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Med Sci Monit. 2011 Dec;17(12): MT105-11. doi: 10.12659/msm.882112.Walecki J, Barcikowska M, Ćwikła JB, Gabryelewicz T. N-acetylaspartate, choline, myoinositol, glutamine and glutamate (glx) concentration changes in proton MR spectroscopy (1H MRS) in patients with mild cognitive impairment (MCI). Med Sci Monit. 2011 Dec;17(12): MT105-11. doi: 10.12659/msm.882112.Coupland NJ, Ogilvie CJ, Hegadoren KM, et al. Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry. 2005 Jun 15;57(12):1526-34. doi: 10.1016/j.biopsych.2005.02.027.Coupland NJ, Ogilvie CJ, Hegadoren KM, et al. Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry. 2005 Jun 15;57(12):1526-34. doi: 10.1016/j.biopsych.2005.02.027.Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr. 1986;6:563-97. doi: 10.1146/annurev.nu.06.070186.003023.Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr. 1986;6:563-97. doi: 10.1146/annurev.nu.06.070186.003023.Zhu X, Schuff N, Kornak J, et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2006 Apr-Jun;20(2):77-85. doi: 10.1097/01.wad.0000213809.12553.fc.Zhu X, Schuff N, Kornak J, et al. Effects of Alzheimer disease on fronto-parietal brain N-acetyl aspartate and myo-inositol using magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2006 Apr-Jun;20(2):77-85. doi: 10.1097/01.wad.0000213809.12553.fc.Kallenberg K, Bock HC, Helms G, et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology. 2009 Dec;253(3): 805-12. doi: 10.1148/radiol.2533071654.Kallenberg K, Bock HC, Helms G, et al. Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology. 2009 Dec;253(3): 805-12. doi: 10.1148/radiol.2533071654.Siger M, Schuff N, Zhu X, et al. Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):57-62. doi: 10.1097/WAD.0b013e3181875434.Siger M, Schuff N, Zhu X, et al. Regional myo-inositol concentration in mild cognitive impairment Using 1H magnetic resonance spectroscopic imaging. Alzheimer Dis Assoc Disord. 2009 Jan-Mar;23(1):57-62. doi: 10.1097/WAD.0b013e3181875434.Herman-Sucharska I, Grzybek M, Grochowska A, et al. Ocena zachowania mioinozytolu w widmie metabolicznym mózgowia (HMRS) u pacjentów z encefalopatia watrobowa [Myoinositol trends in HMRS brain spectrum of patients with hepatic encephalopathy]. Przegl Lek. 2010;67(4):247-50. Polish.Herman-Sucharska I, Grzybek M, Grochowska A, et al. Ocena zachowania mioinozytolu w widmie metabolicznym mózgowia (HMRS) u pacjentów z encefalopatia watrobowa [Myoinositol trends in HMRS brain spectrum of patients with hepatic encephalopathy]. Przegl Lek. 2010;67(4):247-50. Polish.Haroon E, Watari K, Thomas A, et al. Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res. 2009 Jan 30;171(1):10-9. doi: 10.1016/j.pscychresns.2008.03.006.Haroon E, Watari K, Thomas A, et al. Prefrontal myo-inositol concentration and visuospatial functioning among diabetic depressed patients. Psychiatry Res. 2009 Jan 30;171(1):10-9. doi: 10.1016/j.pscychresns.2008.03.006.Wellard RM, Briellmann RS, Prichard JW, et al. Myoinositol abnormalities in temporal lobe epilepsy. Epilepsia. 2003 Jun;44(6):815-21. doi: 10.1046/j.1528-1157.2003.44102.x.Wellard RM, Briellmann RS, Prichard JW, et al. Myoinositol abnormalities in temporal lobe epilepsy. Epilepsia. 2003 Jun;44(6):815-21. doi: 10.1046/j.1528-1157.2003.44102.x.Willmroth F, Drieling T, Lamla U, et al. Sodium-myo-inositol cotransporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol. 2007 Feb;10(1):63-71. doi: 10.1017/S1461145705006371.Willmroth F, Drieling T, Lamla U, et al. Sodium-myo-inositol cotransporter (SMIT-1) mRNA is increased in neutrophils of patients with bipolar 1 disorder and down-regulated under treatment with mood stabilizers. Int J Neuropsychopharmacol. 2007 Feb;10(1):63-71. doi: 10.1017/S1461145705006371.Carrington AL, Calcutt NA, Ettlinger CB, et al. Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol. 1993 Jun 24;237(2-3):257-63. doi: 10.1016/0014-2999(93)90277-o.Carrington AL, Calcutt NA, Ettlinger CB, et al. Effects of treatment with myo-inositol or its 1,2,6-trisphosphate (PP56) on nerve conduction in streptozotocin-diabetes. Eur J Pharmacol. 1993 Jun 24;237(2-3):257-63. doi: 10.1016/0014-2999(93)90277-o.Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep;153(9):1219-21. doi: 10.1176/ajp.153.9.1219.Fux M, Levine J, Aviv A, Belmaker RH. Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry. 1996 Sep;153(9):1219-21. doi: 10.1176/ajp.153.9.1219.Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001 Jun;21(3):335-9. doi: 10.1097/00004714-200106000-00014.Palatnik A, Frolov K, Fux M, Benjamin J. Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder. J Clin Psychopharmacol. 2001 Jun;21(3):335-9. doi: 10.1097/00004714-200106000-00014.Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995 May;152(5):792-4. doi: 10.1176/ajp.152.5.792.Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. Am J Psychiatry. 1995 May;152(5):792-4. doi: 10.1176/ajp.152.5.792.Cavalli P, Tonni G, Grosso E, Poggiani C. Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Res A Clin Mol Teratol. 2011 Nov;91(11):962-5. doi: 10.1002/bdra.22853.Cavalli P, Tonni G, Grosso E, Poggiani C. Effects of inositol supplementation in a cohort of mothers at risk of producing an NTD pregnancy. Birth Defects Res A Clin Mol Teratol. 2011 Nov;91(11):962-5. doi: 10.1002/bdra.22853.Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutr Rev. 2002 Mar;60(3):80-7. doi: 10.1301/00296640260042748.Beemster P, Groenen P, Steegers-Theunissen R. Involvement of inositol in reproduction. Nutr Rev. 2002 Mar;60(3):80-7. doi: 10.1301/00296640260042748.Majerus PW, Wilson DB, Zhang C, et al. Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects. Adv Enzyme Regul. 2010;50(1):365-72. doi: 10.1016/j.advenzreg.2009.10.017.Majerus PW, Wilson DB, Zhang C, et al. Expression of inositol 1,3,4-trisphosphate 5/6-kinase (ITPK1) and its role in neural tube defects. Adv Enzyme Regul. 2010;50(1):365-72. doi: 10.1016/j.advenzreg.2009.10.017.Wilson MP, Hugge C, Bielinska M,et al. Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci USA. 2009 Jun 16;106(24):9831-5. doi: 10.1073/pnas.0904172106.Wilson MP, Hugge C, Bielinska M,et al. Neural tube defects in mice with reduced levels of inositol 1,3,4-trisphosphate 5/6-kinase. Proc Natl Acad Sci USA. 2009 Jun 16;106(24):9831-5. doi: 10.1073/pnas.0904172106.Cogram P, Tesh S, Tesh J, et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod. 2002 Sep;17(9):2451-8. doi: 10.1093/humrep/17.9.2451.Cogram P, Tesh S, Tesh J, et al. D-chiro-inositol is more effective than myo-inositol in preventing folate-resistant mouse neural tube defects. Hum Reprod. 2002 Sep;17(9):2451-8. doi: 10.1093/humrep/17.9.2451.Калачева А.Г., Торшин И.Ю., Стельмашук Е.В., и др. Нейропротекторное действие миоинозитола на клеточной модели глутаматного стресса как основа для профилактики нарушений внутриутробного развития головного мозга. Фармакокинетика и Фармакодинамика. 2018;(3):9-20.Kalacheva AG, Torshin IYu, Stelmashuk EV, et al. Neuroprotective effect of myoinositol on the cellular model of glutamate stress as a basis for the prevention of disorders of intrauterine development of the brain. Pharmacokinetics and Pharmacodynamics. 2018;(3):9-20. (In Russ.). doi: 10.24411/2587-7836-2018-10018.Eriksson UJ, Wentzel P. Diabetic embryopathy. Methods Mol Biol. 2012;889:425-36. doi: 10.1007/978-1-61779-867-2_26.Eriksson UJ, Wentzel P. Diabetic embryopathy. Methods Mol Biol. 2012;889:425-36. doi: 10.1007/978-1-61779-867-2_26.Akashi M, Akazawa S, Akazawa M, et al. Effects of insulin and myo-inositol on embryo growth and development during early organogenesis in streptozocin-induced diabetic rats. Diabetes. 1991 Dec;40(12):1574-9. doi: 10.2337/diab.40.12.1574.Akashi M, Akazawa S, Akazawa M, et al. Effects of insulin and myo-inositol on embryo growth and development during early organogenesis in streptozocin-induced diabetic rats. Diabetes. 1991 Dec;40(12):1574-9. doi: 10.2337/diab.40.12.1574.Khandelwal M, Reece EA, Wu YK, Borenstein M. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology. 1998 Feb;57(2):79-84. doi: 10.1002/(SICI)1096-9926(199802)57:2<79::AID-TERA6>3.0.CO;2-1.Khandelwal M, Reece EA, Wu YK, Borenstein M. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology. 1998 Feb;57(2):79-84. doi: 10.1002/(SICI)1096-9926(199802)57:2<79::AID-TERA6>3.0.CO;2-1.Cogram P, Hynes A, Dunlevy LP, et al. Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum Mol Genet. 2004 Jan 1;13(1):7-14. doi: 10.1093/hmg/ddh003.Cogram P, Hynes A, Dunlevy LP, et al. Specific isoforms of protein kinase C are essential for prevention of folate-resistant neural tube defects by inositol. Hum Mol Genet. 2004 Jan 1;13(1):7-14. doi: 10.1093/hmg/ddh003.Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6. PMID: 21845803.Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci. 2011 Aug;15(8):931-6. PMID: 21845803.Громова О.А., Торшин И.Ю., Уварова Е.В. и др. Систематический анализ биологических ролей и фармакологических свойств D-хироинозитола. Гинекология. 2020;22(3):21-28.Gromova OA, Torshin IYu, Uvarova EV, et al. Systematic analysis of the biological roles and pharmacological properties of D-chiro-inositol. Gynecology. 2020;22(3):21-28. (In Russ.). doi: 10.26442/20795696.2020.3.200210.Fan C, Liang W, Wei M, et al. Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Front Pharmacol. 2020 Mar 26;11:354. doi: 10.3389/fphar.2020.00354.Fan C, Liang W, Wei M, et al. Effects of D-Chiro-Inositol on Glucose Metabolism in db/db Mice and the Associated Underlying Mechanisms. Front Pharmacol. 2020 Mar 26;11:354. doi: 10.3389/fphar.2020.00354.Ostlund RE Jr, McGill JB, Herskowitz I, et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9988-92. doi: 10.1073/pnas.90.21.9988.Ostlund RE Jr, McGill JB, Herskowitz I, et al. D-chiro-inositol metabolism in diabetes mellitus. Proc Natl Acad Sci U S A. 1993 Nov 1;90(21):9988-92. doi: 10.1073/pnas.90.21.9988.La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015 Jan;31(1):52-6. doi: 10.3109/09513590.2014.964201.La Marca A, Grisendi V, Dondi G, et al. The menstrual cycle regularization following D-chiro-inositol treatment in PCOS women: a retrospective study. Gynecol Endocrinol. 2015 Jan;31(1):52-6. doi: 10.3109/09513590.2014.964201.Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002 Nov-Dec;8(6):417-23. doi: 10.4158/EP.8.6.417.Iuorno MJ, Jakubowicz DJ, Baillargeon JP, et al. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract. 2002 Nov-Dec;8(6):417-23. doi: 10.4158/EP.8.6.417.Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med. 1999 Apr 29;340(17):1314-20. doi: 10.1056/NEJM199904293401703.Cheng F, Han L, Xiao Y, et al. d-chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/ AKT Pathway. J Agric Food Chem. 2019 May 29;67(21):5957-5967. doi: 10.1021/acs.jafc.9b01253.Cheng F, Han L, Xiao Y, et al. d-chiro-Inositol Ameliorates High Fat Diet-Induced Hepatic Steatosis and Insulin Resistance via PKCε-PI3K/ AKT Pathway. J Agric Food Chem. 2019 May 29;67(21):5957-5967. doi: 10.1021/acs.jafc.9b01253.Zhao SS, Li NR, Zhao WL, et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin. 2018 Feb;39(2):213-221. doi: 10.1038/aps.2017.98.Zhao SS, Li NR, Zhao WL, et al. D-chiro-inositol effectively attenuates cholestasis in bile duct ligated rats by improving bile acid secretion and attenuating oxidative stress. Acta Pharmacol Sin. 2018 Feb;39(2):213-221. doi: 10.1038/aps.2017.98.Zhao M, Song B, Pu J, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006 Jul 27;442(7101):457-60. doi: 10.1038/nature04925.Zhao M, Song B, Pu J, et al. Electrical signals control wound healing through phosphatidylinositol-3-OH kinase-gamma and PTEN. Nature. 2006 Jul 27;442(7101):457-60. doi: 10.1038/nature04925.Guo MF, Yu JZ, Ma CG. Mechanisms related to neuron injury and death in cerebral hypoxic ischaemia. Folia Neuropathol. 2011;49(2):78-87.Guo MF, Yu JZ, Ma CG. Mechanisms related to neuron injury and death in cerebral hypoxic ischaemia. Folia Neuropathol. 2011;49(2):78-87.Функциональная ангиоархитектоника головного мозга / И.В. Ганнушкина, В.П. Шафранова, Т.В. Рясина ; Акад. мед. наук СССР. Москва : Медицина, 1977. 240 с.Funkcional'naya angioarhitektonika golovnogo mozga. Gannushkina IV, Shafranova VP, Ryasina TV. AMN SSSR. Moscow: Medicina. 1977. (In Russ.)Hernández-Fonseca K, Cárdenas-Rodríguez N, Pedraza-Chaverri J, Massieu L. Calcium-dependent production of reactive oxygen species is involved in neuronal damage induced during glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res. 2008 Jun;86(8):1768-80. doi: 10.1002/jnr.21634.Hernández-Fonseca K, Cárdenas-Rodríguez N, Pedraza-Chaverri J, Massieu L. Calcium-dependent production of reactive oxygen species is involved in neuronal damage induced during glycolysis inhibition in cultured hippocampal neurons. J Neurosci Res. 2008 Jun;86(8):1768-80. doi: 10.1002/jnr.21634.

The authors declare that there are no conflicts of interest present.